NEWS & ARTICLE
2026.02.01
Appointment of Chief Operating Officer
Myrodia Therapeutics Co., Ltd. (“the Company”) is pleased to announce that Mr. Minoru Kobayashi has been appointed as Chief Operating Officer (COO), effective February 1, 2026.
With over 30 years of experience at a Japanese pharmaceutical company, Mr. Kobayashi has built a broad track record spanning R&D, product development, and corporate strategy.
He is recognized for decision-making that effectively bridges science and business, and has served as an operations leader on a range of strategic initiatives.
These include developing therapeutic area strategies, obtaining U.S. regulatory approval of an anti-Parkinson’s disease therapy, securing domestic approval of an anti-psoriasis antibody developed through international collaboration, and formulating mid-term corporate plans.
The Company believes Mr. Kobayashi’s leadership will further strengthen its R&D execution and operational foundation as it continues to advance its mission.